Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with apatinib for intermediate and advanced hepatocellular carcinoma
ChiCTR1800018621Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Progression-free survival. Started Sep 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800018621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018621.